Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression
Phase I interventional study (n=100) using ketamine-induced gamma band potentiation (GBP) in healthy, MDD and TRD groups to prognose 4-week antidepressant outcome across an induction course.
Details
This study tests whether ketamine-induced EEG gamma band potentiation (GBP) predicts 4-week antidepressant outcome; healthy controls, MDD and TRD groups are included to dissociate disease and medication-specific effects.
Design uses fixed-order, single-blind saline-versus-ketamine crossover EEG assessments (infusion 1 for all groups; infusion 4 for TRD), and an eight-infusion induction course for TRD participants to capture real-world treatment variation.
Outcomes include GBP measures (>30 Hz) and clinical symptom change (MADRS) at 4 weeks; results will inform the translational utility of GBP as a prognostic biomarker for neuromodulatory therapies.